Photo from wikipedia
OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/ R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING A. Chiappella* | T.E. Witzig… Click to show full abstract
OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/ R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING A. Chiappella* | T.E. Witzig | U. Vitolo | R. Gascoyne | J. Russo | B. Amoroso | K. Hudak | A. Ogunkanmi | Y. Xu | W. Ruiz | S. Singh | G.S. Nowakowski Division of Hematology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; Division of Hematology, Mayo Clinic, Rochester, MN, USA; Pathology and Lymphoid Cancer Research, British Columbia Cancer Agency, Vancouver, BC, Canada; Hematology/Oncology, Celgene Corporation, Summit, NJ, USA; Hematology/Oncology, Celgene Sàrl, Boudry, Switzerland; Hematology/ Oncology, Celgene Corporation, Shanghai, China; Clinical Research and Development, Celgene K.K., Tokyo, Japan; Clinical Operations, Celgene Corporation, Summit, NJ, USA
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!